170 related articles for article (PubMed ID: 19718465)
1. The effects of hyperglycaemia on thrombin-activatable fibrinolysis inhibitor.
Verkleij CJ; Nieuwdorp M; Gerdes VE; Mörgelin M; Meijers JC; Marx PF
Thromb Haemost; 2009 Sep; 102(3):460-8. PubMed ID: 19718465
[TBL] [Abstract][Full Text] [Related]
2. The role of thrombin-activatable fibrinolysis inhibitor in diabetic wound healing.
Verkleij CJ; Roelofs JJ; Havik SR; Meijers JC; Marx PF
Thromb Res; 2010 Nov; 126(5):442-6. PubMed ID: 20828799
[TBL] [Abstract][Full Text] [Related]
3. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
Colucci M; Binetti BM; Branca MG; Clerici C; Morelli A; Semeraro N; Gresele P
Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
[TBL] [Abstract][Full Text] [Related]
4. Postprandial thrombin activatable fibrinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients.
Rigla M; Wägner AM; Borrell M; Mateo J; Foncuberta J; de Leiva A; Ordóñez-Llanos J; Pérez A
Metabolism; 2006 Nov; 55(11):1437-42. PubMed ID: 17046544
[TBL] [Abstract][Full Text] [Related]
5. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
Kitagawa N; Yano Y; Gabazza EC; Bruno NE; Araki R; Matsumoto K; Katsuki A; Hori Y; Nakatani K; Taguchi O; Sumida Y; Suzuki K; Adachi Y
Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
[TBL] [Abstract][Full Text] [Related]
6. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
[TBL] [Abstract][Full Text] [Related]
7. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
8. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin.
Mosnier LO; Meijers JC; Bouma BN
Thromb Haemost; 2001 Jan; 85(1):5-11. PubMed ID: 11204587
[TBL] [Abstract][Full Text] [Related]
9. Thrombin-activatable fibrinolysis inhibitor activity and global fibrinolytic capacity in Type 1 diabetes: evidence for normal fibrinolytic state.
Harmanci A; Kandemir N; Dagdelen S; Gonc N; Buyukasik Y; Alikasifoglu A; Kirazli S; Ozon A; Gurlek A
J Diabetes Complications; 2006; 20(1):40-4. PubMed ID: 16389166
[TBL] [Abstract][Full Text] [Related]
10. Quantification of the effects of thrombin activatable fibrinolysis inhibitor and alpha2-antiplasmin on fibrinolysis in normal human plasma.
Nielsen VG; Ellis TC
Blood Coagul Fibrinolysis; 2007 Jan; 18(1):29-33. PubMed ID: 17179823
[TBL] [Abstract][Full Text] [Related]
11. The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis.
Mosnier LO; Meijers JC; Bouma BN
Thromb Haemost; 2001 Oct; 86(4):1040-6. PubMed ID: 11686322
[TBL] [Abstract][Full Text] [Related]
12. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.
Von dem Borne PA; Bajzar L; Meijers JC; Nesheim ME; Bouma BN
J Clin Invest; 1997 May; 99(10):2323-7. PubMed ID: 9153272
[TBL] [Abstract][Full Text] [Related]
13. Protein C inhibitor regulates the thrombin-thrombomodulin complex in the up- and down regulation of TAFI activation.
Mosnier LO; Elisen MG; Bouma BN; Meijers JC
Thromb Haemost; 2001 Oct; 86(4):1057-64. PubMed ID: 11686324
[TBL] [Abstract][Full Text] [Related]
14. [Thrombin activatable fibrinolysis inhibitor (TAFI) in allergic asthma patients].
Kemona-Chetnik I; Kowal K; Kucharewicz I; Pampuch A; Bodzenta-Lukaszyk A
Przegl Lek; 2006; 63(12):1281-5. PubMed ID: 17642140
[TBL] [Abstract][Full Text] [Related]
15. Thrombin activatable fibrinolysis inhibitor in hypertensive kidney transplant recipients.
Malyszko J; Malyszko JS; Hryszko T; Mysliwiec M
Transplant Proc; 2006; 38(1):105-7. PubMed ID: 16504676
[TBL] [Abstract][Full Text] [Related]
16. Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation.
Colucci M; Semeraro N
Thromb Res; 2012 Mar; 129(3):314-9. PubMed ID: 22113149
[TBL] [Abstract][Full Text] [Related]
17. [Thrombin activatable fibrinolysis inhibitor (TAFI) and its importance in the regulation of fibrinolysis].
Stasko J; Hudecek J; Kubisz P
Vnitr Lek; 2004 Jan; 50(1):36-44. PubMed ID: 15015228
[TBL] [Abstract][Full Text] [Related]
18. Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia?
Dusse LM; Cooper AJ; Lwaleed BA
Clin Chim Acta; 2007 Mar; 378(1-2):1-6. PubMed ID: 17184758
[TBL] [Abstract][Full Text] [Related]
19. Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy.
Małyszko J; Małyszko JS; Hryszko T; Myśliwiec M
Thromb Haemost; 2004 Mar; 91(3):480-6. PubMed ID: 14983223
[TBL] [Abstract][Full Text] [Related]
20. Contact activation prolongs clot lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and Factor XIII.
Nielsen VG; Steenwyk BL; Gurley WQ
J Heart Lung Transplant; 2006 Oct; 25(10):1247-52. PubMed ID: 17045938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
